The evolving treatment options for diabetic macular edema

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Jain, Atul ^a   Varshney, Neeta ^b   Smith, Colin ^a  

^a San Diego CA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OCRIPLASMIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BLOOD PRESSURE REGULATION; CATARACT; CATARACT EXTRACTION; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DISEASE DURATION; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EYE PROTECTION; GLAUCOMA; GLAUCOMA SURGERY; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84885350201     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/689276     Document Type: Review

References (67)

1. Centers for Disease Control and Prevention, National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and pre Diabetes in the United States, 2011 2011 Atlanta, Ga, USA Department of Health and Human Services, Centers for Disease Control and Prevention
2. Jain A., Sarraf D., Fong D., Preventing diabetic retinopathy through control of systemic factors. Current Opinion in Ophthalmology 2003 14 6 389 394 2-s2.0-1542616633 10.1097/00055735-200312000-00012 (Pubitemid 38333578)
3. Blumenkranz M. S., Optimal current and future treatments for diabetic macular oedema. Eye 2010 24 3 428 434 2-s2.0-77949445943 10.1038/eye.2009.335
4. Kempen J. H., O'Colmain B. J., Leske M. C., Haffner S. M., Klein R., Moss S. E., Taylor H. R., Hamman R. F., West S. K., Wang J. J., Congdon N. G., Friedman D. S., The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology 2004 122 4 552 563 2-s2.0-11144356305 10.1001/archopht.122.4.552 (Pubitemid 38456292)
5. Narayan K. M. V., Boyle J. P., Geiss L. S., Saaddine J. B., Thompson T. J., Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006 29 9 2114 2116 2-s2.0-33845341470 10.2337/dc06-1136 (Pubitemid 44871196)
6. Ding J., Wong T. Y., Current epidemiology of diabetic retinopathy and diabetic macular edema. Current Diabetes Reports 2012 12 4 346 354
7. Yau J. W. Y., Rogers S. L., Kawasaki R., Lamoureux E. L., Kowalski J. W., Bek T., Chen S.-J., Dekker J. M., Fletcher A., Grauslund J., Haffner S., Hamman R. F., Ikram M. K., Kayama T., Klein B. E. K., Klein R., Krishnaiah S., Mayurasakorn K., O'Hare J. P., Orchard T. J., Porta M., Rema M., Roy M. S., Sharma T., Shaw J., Taylor H., Tielsch J. M., Varma R., Wang J. J., Wang N., West S., Zu L., Yasuda M., Zhang X., Mitchell P., Wong T. Y., Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012 35 3 556 564 2-s2.0-84859030420 10.2337/dc11-1909
8. Narayan K. M. V., Boyle J. P., Thompson T. J., Sorensen S. W., Williamson D. F., Lifetime risk for diabetes mellitus in the United States. Journal of the American Medical Association 2003 290 14 1884 1890 2-s2.0-0141991939 10.1001/jama.290.14.1884 (Pubitemid 37430605)
9. Photocoagulation for Diabetic Macular Edema, Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Archives of Ophthalmology 1985 103 12 1796 1806
10. Klaassen I., Van Noorden C. J., Schlingemann R. O., Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Progress in Retinal and Eye Research 2013 34 19 48
11. Joussen A. M., Poulaki V., Le M. L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T. S., Adamis A. P., A central role for inflammation in the pathogenesis of diabetic retinopathy. The FASEB Journal 2004 18 12 1450 1452 2-s2.0-7044228789 10.1096/fj.03-1476fje (Pubitemid 39561611)
12. Joussen A. M., Poulaki V., Mitsiades N., Cai W.-Y., Suzuma I., Pak J., Ju S.-T., Rook S. L., Esser P., Mitsiades C. S., Kirchhof B., Adamis A. P., Aiello L. P., Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. The FASEB Journal 2003 17 1 76 78 2-s2.0-0037271803
13. Antcliff R. J., Marshall J., The pathogenesis of edema in diabetic maculopathy. Seminars in Ophthalmology 1999 14 4 223 232 2-s2.0-0033400347 (Pubitemid 30061165)
14. Tolentino M. J., Miller J. W., Gragoudas E. S., Jakobiec F. A., Flynn E., Chatzistefanou K., Ferrara N., Adamis A. P., Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996 103 11 1820 1828 2-s2.0-0029803087 (Pubitemid 26403735)
15. Carmeliet P., Jain R. K., Molecular mechanisms and clinical applications of angiogenesis. Nature 2011 473 7347 298 307 2-s2.0-79956328903 10.1038/nature10144
16. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., Suzuma I., Ohashi H., Ojima T., Murakami T., Kobayashi T., Masuda S., Nagao M., Yoshimura N., Takagi H., Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. The New England Journal of Medicine 2005 353 8 782 792 2-s2.0-23944523376 10.1056/NEJMoa041773 (Pubitemid 41215487)
17. Cai W., Rook S. L., Jiang Z. Y., Takahara N., Aiello L. P., Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Investigative Ophthalmology and Visual Science 2000 41 7 1885 1893 2-s2.0-0034043446 (Pubitemid 30354364)
18. Muni R. H., Kohly R. P., Lee E. Q., rospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmology 2013 131 4 514 521
19. Wang S., Park J. K., Duh E. J., Novel targets against retinal angiogenesis in diabetic retinopathy. Current Diabetes Reports 2012 12 4 355 363
20. Owen L. A., Hartnett M. E., Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Current Diabetes Reports 2013 13 4 476 480 10.1007/s11892-013-0382-z
21. Funatsu H., Noma H., Mimura T., Eguchi S., Hori S., Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009 116 1 73 79 2-s2.0-57949110908 10.1016/j.ophtha.2008.09.037
22. Brownlee M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 6 1615 1625 2-s2.0-20044376702 10.2337/diabetes.54. 6.1615 (Pubitemid 40770750)
23. Wang Y., Wang S., Sheibani N., Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. Microvascular Research 2006 71 3 143 151 2-s2.0-33646922275 10.1016/j.mvr.2006.02.004 (Pubitemid 43794860)
24. Funatsu H., Noma H., Mimura T., Eguchi S., Hori S., Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009 116 1 73 79 2-s2.0-57949110908 10.1016/j.ophtha.2008.09.037
25. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The New England Journal of Medicine 2000 342 6 381 389
26. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1993 329 14 977 986 10.1056/NEJM199309303291401 (Pubitemid 23307905)
27. The Diabetes Control and Complications Trial, The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the diabetes control and complications trial. Archives of Ophthalmology 1995 113 1 36 51 2-s2.0-0028833239
28. The Diabetes Control and Complications Trial Research Group, Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995 102 4 647 661
29. The Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The New England Journal of Medicine 2000 342 6 381 389 10.1056/NEJM200002103420603 (Pubitemid 30084536)
30. White N. H., Sun W., Cleary P. A., Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology 2008 126 12 1707 1715
31. Turner R., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 352 9131 837 853 2-s2.0-0032511583 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
32. The United Kingdom Prospective Diabetes Study Group, ETight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1999 317 7160 703 713 2-s2.0-0033514015
33. Early Treatment Diabetic Retinopathy Study Group, Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Archives of Ophthalmology 1985 103 12 1796 1806
34. Fong D. S., Strauber S. F., Aiello L. P., Beck R. W., Callanan D. G., Danis R. P., Davis M. D., Feman S. S., Ferris F., Friedman S. M., Garcia C. A., Glassman A. R., Han D. P., Le D., Kollman C., Lauer A. K., Recchia F. M., Solomon S. D., Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Archives of Ophthalmology 2007 125 4 469 480 2-s2.0-34247164981 10.1001/archopht.125.4.469 (Pubitemid 46596718)
35. Jain A., Collen J., Kaines A., Hubschman J.-P., Schwartz S., Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes. Retina 2010 30 10 1622 1626 2-s2.0-78649361236 10.1097/IAE.0b013e3181e095d8
36. Sivaprasad S., Elagouz M., McHugh D., Shona O., Dorin G., Micropulsed diode laser therapy: evolution and clinical applications. Survey of Ophthalmology 2010 55 6 516 530 2-s2.0-77957753652 10.1016/j.survophthal.2010. 02.005
37. Witkin A. J., Brown G. C., Update on nonsurgical therapy for diabetic macular edema. Current Opinion in Ophthalmology 2011 22 3 185 189 2-s2.0-79955073933 10.1097/ICU.0b013e3283459724
38. Soheilian M., Garfami K. H., Ramezani A., Yaseri M., Peyman G. A., Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012 32 2 314 321 2-s2.0-84856598999 10.1097/IAE.0b013e31822f55de
39. Diabetic Retinopathy Clinical Research Network, Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology 2009 127 3 245 251
40. Rajendram R., Fraser-Bell S., Kaines A., A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology 2012 130 8 972 979
41. Pan-American Collaborative Retina Study Group (PACORES), Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months. Retina 2013 33 2 403 413
42. Audren F., Lecleire-Collet A., Erginay A., Haouchine B., Benosman R., Bergmann J.-F., Gaudric A., Massin P., Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. American Journal of Ophthalmology 2006 142 5 794.e8 799.e8 2-s2.0-33750051350 10.1016/j.ajo.2006.06.011 (Pubitemid 44584138)
43. Gillies M. C., Sutter F. K. P., Simpson J. M., Larsson J., Ali H., Zhu M., Intravitreal triamcinolone for refractory diabetic macular edema. Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006 113 9 1533 1538 2-s2.0-33747623255 10.1016/j.ophtha.2006.02. 065 (Pubitemid 44292310)
44. Diabetic Retinopathy Clinical Research Network, A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008 115 9 1447 1449
45. Kuppermann B. D., Blumenkranz M. S., Haller J. A., Williams G. A., Weinberg D. V., Chou C., Whitcup S. M., Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology 2007 125 3 309 317 2-s2.0-33947275043 10.1001/archopht.125.3.309 (Pubitemid 46425557)
46. Pearson P. A., Comstock T. L., Ip M., Callanan D., Morse L. S., Ashton P., Levy B., Mann E. S., Eliott D., Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011 118 8 1580 1587 2-s2.0-79961044911 10.1016/j.ophtha.2011.02.048
47. FAME Study Group, Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012 119 10 2125 2132
48. Campochiaro P. A., Hafiz G., Shah S. M., Bloom S., Brown D. M., Busquets M., Ciulla T., Feiner L., Sabates N., Billman K., Kapik B., Green K., Kane F., Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010 117 7 1393 1399 2-s2.0-77954349303 10.1016/j.ophtha.2009.11. 024
49. Haller J. A., Kuppermann B. D., Blumenkranz M. S., Williams G. A., Weinberg D. V., Chou C., Whitcup S. M., Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology 2010 128 3 289 296 2-s2.0-77749330682 10.1001/archophthalmol.2010.21
50. Ozurdex CHAMPLAIN Study Group, Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011 31 5 915 923 2-s2.0-79955558683 10.1097/IAE.0b013e318206d18c
51. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
52. Macugen 1013 Study Group, A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011 118 6 1107 1118 2-s2.0-79958012399 10.1016/j.ophtha.2011.02.045
53. RISE and RIDE Research Group, Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology 2012 119 4 789 801 2-s2.0-84859268292 10.1016/j.ophtha.2011.12.039
54. RESTORE Study Group, The restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Evidence-Based Ophthalmology 2011 12 4 206 207 2-s2.0-80053954632 10.1097/IEB.0b013e31822faded
55. READ-2 Study Group, Primary end point (Six Months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009 116 11 2175 2181 2-s2.0-70350567637 10.1016/j.ophtha.2009.04.023
56. READ-2 Study Group, Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010 117 11 2146 2151
57. Massin P., Bandello F., Garweg J. G., Hansen L. L., Harding S. P., Larsen M., Mitchell P., Sharp D., Wolf-Schnurrbusch U. E. K., Gekkieva M., Weichselberger A., Wolf S., Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010 33 11 2399 2405 2-s2.0-79251606719 10.2337/dc10-0493
58. DA VINCI Study Group, One-year outcomes of the DA VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012 119 8 1658 1665 2-s2.0-84859937024 10.1016/j.ophtha.2012.02.010
59. Diabetic Retinopathy Clinical Research Network, Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012 119 11 2312 2318
60. Diabetic Retinopathy Clinical Research Network, Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011 118 4 609 614 2-s2.0-79953299899 10.1016/j.ophtha.2010.12.033
61. Pan-American Collaborative Retina Study Group (PACORES), Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 6 735 743 2-s2.0-67349157689 10.1007/s00417-008-1034-x
62. Harbour J. W., Smiddy W. E., Flynn H. W. Jr., Rubsamen P. E., Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. American Journal of Ophthalmology 1996 121 4 405 413 2-s2.0-0029949176 (Pubitemid 26113283)
63. Diabetic Retinopathy Clinical Research Network Writing Committee, Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010 117 6 1087.e3 1093.e3
64. Flaxel C. J., Edwards A. R., Aiello L. P., Arrigg P. G., Beck R. W., Bressler N. M., Bressler S. B., Ferris F. L., Gupta S. K., Haller J. A., Lazarus H. S., Qin H., Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina 2010 30 9 1488 1495 2-s2.0-77958576096 10.1097/IAE.0b013e3181e7974f
65. Yanyali A., Aytug B., Horozoglu F., Nohutcu A. F., Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. American Journal of Ophthalmology 2007 144 1 124 126 2-s2.0-34250774079 10.1016/j.ajo.2007.02.048 (Pubitemid 46963178)
66. Saeed A. M., Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema. Journal of Clinical Ophthalmology 2013 7 283 297
67. Lopez-Lopez F., Rodriguez-Blanco M., Gómez-Ulla F., Marticonera J., Enzymatic vitreolysis. Current Diabetes Reviews 2009 5 1 57 62 2-s2.0-65549165049 10.2174/157339909787314220